Artificial Intelligence (AI) in Respiratory Diseases Global Market Report 2024

The AI in respiratory diseases market size has grown strongly in recent years. It will grow from $7.25 billion in 2023 to $7.66 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. The growth observed in the historical period can be attributed to several factors, including the escalation of government regulations, mounting environmental concerns, a growing aging population, the adoption of patient-centric healthcare approaches, and an upsurge in healthcare infrastructure development.

The AI in respiratory diseases market size is expected to see steady growth in the next few years. It will grow to $9.35 billion in 2028 at a compound annual growth rate (CAGR) of 3.8%. The anticipated growth in the forecast period can be attributed to several factors, including the increasing prevalence of respiratory diseases, a rising need for early detection and diagnosis, growing environmental pollution, an upswing in healthcare expenditure, and ongoing research and development initiatives. Notable trends expected in the forecast period encompass technological advancements, advancements in drug discovery and development, personalized treatment plans, and the increasing adoption of telemedicine and remote patient monitoring, emphasizing the importance of remote patient monitoring.

The escalating issue of environmental pollution is anticipated to drive the advancement of artificial intelligence (AI) within the respiratory disease market in the foreseeable future. Environmental pollution, characterized by the rapid addition of ssubstances or energy to the environment beyond its capacity for dispersion or harmless storage, poses a significant threat to respiratory health. AI applications in respiratory diseases hold promise in mitigating the adverse effects of environmental pollution by providing real-time monitoring, personalized risk assessments, informed decision-making, and innovative solutions for individuals and communities. For example, data from the United States Environmental Protection Agency revealed that in 2022, approximately 66 million tons of pollution were emitted into the atmosphere in the US, with greenhouse gas emissions increasing from 6.02 billion metric tons (MMT) of CO2 in 2020 to 6,340.23 MMT of CO2 in 2021. Thus, the surge in environmental pollution is a catalyst for the expansion of AI in the respiratory disease market.

Key players in the artificial intelligence (AI) segment of the respiratory diseases market are innovating with products such as N-Tidal devices designed to monitor patients' tidal breathing patterns. The N-Tidal device measures the volume of air exchanged during normal breathing, providing crucial insights into lung function. For instance, in August 2023, TidalSense, a UK-based respiratory technology company, introduced N-Tidal, an AI-regulated technology tailored for the diagnosis and management of chronic obstructive pulmonary disease (COPD). This technology integrates N-Tidal's CO2 sensor data with an AI platform to track changes in lung function, enhancing COPD diagnosis and management. Clinical studies have demonstrated the technology's high accuracy, promising to revolutionize the diagnostic process for respiratory ailments. The launch represents a significant milestone in leveraging AI for respiratory disease assessment, offering a more convenient and efficient alternative to traditional diagnostic methodologies.

In July 2023, ResMed Inc., a prominent US-based medical equipment provider renowned for its cloud-connectable medical devices, finalized the acquisition of Somnoware for an undisclosed sum. This strategic move bolsters ResMed's portfolio in sleep and respiratory care while synergizing with its current suite of digital respiratory healthcare solutions. The acquisition is poised to elevate patient care by optimizing the management of patient data, streamlining equipment ordering, scheduling appointments, and monitoring compliance. Ultimately, these enhancements are expected to elevate patient experience and health outcomes. Somnoware, a US-based cloud platform, specializes in advanced respiratory care management and hospital-at-home solutions, aligning seamlessly with ResMed's commitment to innovation and excellence in healthcare.

Major companies operating in the artificial intelligence (ai) in respiratory diseases market report are Siemens Healthineers, Philips Healthcare, General Electric (GE) Healthcare, Verily Life Sciences LLC, DeepMind Health, Merative L.P., Innovaccer, Freenome, Aidoc Medical, Butterfly Network, Infervision, Imagen Technologies, Caption Health, Gauss Surgical Inc., Swaasa AI, Inspirata Inc., VIDA Diagnostics Inc., Enlitic, Thirona B.v., ArtiQ, Icometrix, Zynnon AG, Aidence, Arterys, Dectrocel Healthcare, PneumoWave Ltd.

North America was the largest region in the artificial Intelligence (AI) in respiratory diseases market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (ai) in respiratory diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (ai) in respiratory diseases market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Artificial intelligence (AI) in the context of respiratory diseases involves leveraging AI and machine learning techniques to assist healthcare professionals in diagnosing, managing, and treating various respiratory conditions. This technology holds significant potential across pulmonary medicine, offering applications in image analysis, predictive modeling, and disease management.

The primary imaging modalities in artificial intelligence (AI) for respiratory diseases include magnetic resonance imaging (MRI), computed tomography (CT) scans, and electronic patient-reported outcomes (ePRO). In the realm of chronic obstructive pulmonary disease (COPD), AI is applied to aid in the diagnosis, management, and treatment of this condition. Its applications extend to various indications such as chronic obstructive pulmonary disease, interstitial lung disease, and pulmonary infections. These AI technologies find utilization in diverse healthcare settings, including hospitals, diagnostic centers, ambulatory surgical centers, and other medical facilities.

The artificial intelligence (AI) respiratory disease market research report is one of a series of new reports that provides artificial intelligence (AI) respiratory disease market statistics, including artificial intelligence (AI) respiratory disease industry global market size, regional shares, competitors with an artificial intelligence (AI) respiratory disease market share, detailed artificial intelligence (AI) respiratory disease market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI) respiratory disease industry. This artificial intelligence (AI) respiratory disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The artificial Intelligence (AI) in respiratory diseases market includes revenues earned by entities by providing services such as AI-assisted imaging analysis, digital pathology platforms, and AI-powered rehabilitation programs. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The AI in respiratory diseases market also includes sales IoT devices, wearables, and smart inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.